ERBB2 and gastric cancer: Moreover, several recent targeted therapy trials have been unsuccessful (10, 11) and, to date, standard treatments of advanced GC consist of 5-FU/platinum based chemotherapy and only two biological agents, trastuzumab for HER2 positive tumors and ramucirumab for chemo-refractory patients (12, 13).